

***HLA-B 1502 GENOTYPE, CARBAMAZEPINE HYPERSENSITIVITY,
SALIVA*****Test ID: HL150****Secondary ID: 60348**

NOTE: Effective with this change, all orders placed for this test must be submitted in the alpha-numeric character Test ID format instead of the numeric Secondary ID. Result codes may also be subject to change. Please review Test Set-Up and Conversion Mapping information at: <http://www.mayomedicallaboratories.com/test-notifications/index.html>

EXPLANATION: Test HL150 will undergo changes in the following categories: method, test classification, reporting name, and days performed.

CURRENT METHODOLOGY: Allele-Specific Polymerase Chain Reaction (PCR) Amplification

NEW METHODOLOGY: Qualitative allele-specific real-time Polymerase Chain Reaction (PCR)

CURRENT TEST CLASSIFICATION: This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

NEW TEST CLASSIFICATION: This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CURRENT REPORTING NAME: HLAB 1502 Genotype, Saliva

NEW REPORTING NAME: HLAB 1502 Carbamazepine, Saliva

CURRENT DAYS PERFORMED: Tuesday and Friday

NEW DAYS PERFORMED: Monday and Thursday

QUESTIONS: Contact your Mayo Medical Laboratories' Regional Manager or Shirley Pokorski, MML Laboratory Technologist Resource Coordinator
Telephone: 800-533-1710